GlassScriptPhysician profile
Jeffries L Bucci
NPI 1093782153
$1,479.22
in general payments reported to CMS, 2019-2025
22 companies · $350 in 2025
The $350 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2021: $97.12 · 2022: $164 · 2023: $215 · 2024: $472 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $231.84 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $184.65 | 2019-2024 | |
| Cranial Technologies, INC | $171.66 | 2019-2023 | Doc Band |
| Glaxosmithkline, LLC. | $153.96 | 2021-2024 | Bexsero |
| Pfizer INC. | $150.20 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $124.77 | 2025 | Jornay Pm |
| Tris Pharma INC | $77.70 | 2021-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $54.14 | 2019-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Alk-Abello, INC | $52.22 | 2025 | Neffy, Grastek, Odactra |
| Corium, LLC | $34.12 | 2025 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $32.32 | 2025 | Zoryve |
| Lnhc, INC | $25.12 | 2025 | Zelsuvmi |
| Neos Therapeutics, LP | $21.86 | 2024 | Adzenys Xr-Odt |
| Shire North American Group INC | $21.00 | 2019 | |
| Genentech USA, INC. | $20.45 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $18.96 | 2024 | Nayzilam |
| Sanofi Pasteur INC. | $18.54 | 2023 | |
| Verrica Pharmaceuticals INC. | $18.04 | 2023 | Ycanth |
| Alexion Pharmaceuticals, INC. | $17.76 | 2023 | Strensiq |
| Vertical Pharmaceuticals, LLC | $17.64 | 2024 | Relexxii |
| Seqirus USA INC | $17.29 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $14.98 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffries Bucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.